Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma

Br J Haematol. 2019 Jul;186(1):140-144. doi: 10.1111/bjh.15716. Epub 2018 Dec 11.
No abstract available

Keywords: daratumumab; multiple myeloma; pomalidomide; refractory; resistance.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Dexamethasone / therapeutic use
  • Drug Resistance, Neoplasm*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use

Substances

  • Antibodies, Monoclonal
  • daratumumab
  • Thalidomide
  • Dexamethasone
  • pomalidomide